



TMU-Research Center of Urology and Kidney Monthly Meeting

Times : **2025/5/22(Thursday) 9:00-10:00**

Google meet link : <https://meet.google.com/ihn-wugo-jfv>

Meeting Chairperson : Kuan-Yu Hung

Participant :

【TMUH】 Ming-Che Liu 、 Yao-Chou Tsai 、 Shauh-Der Yeh 、 Chien-Chih Wu 、 Hsiao-Yu Lin 、 Jeng-Cheng Wu 、 Ching-Hsin Chang 、 Wei-Chieh Chen 、 Fang-Yu Ku 、 Shih-Hsiu Lo 、 Te-Chao Fang 、 Hsi-Hsien Chen 、 Yen-Chung Lin 、 Chih-Chin Kao 、 Ching-Yi Chen 、 Shu-Ching Yeh 、 TING-EN TAI

【WFH】 Yu-Ching Wen 、 Liang-Ming Lee 、 Ke-Hsun Lin 、 Yung-Wei Lin 、 Chi-Hao Hsiao 、 Syuan-Hao Syu 、 Chung-Howe Lai 、 Yung-Ho Hsu 、 Chih-Chen Hsu 、 Tso-Hsiao Chen 、 Cho-Hsing Chung 、 Chung-Yi Cheng 、 Chung-Te Liu 、 Yun-Hong Yang 、 Ming-Che Lee 、 Yueh-Lin Wu 、 I-Wen Wu

【SHH】 Mai-Szu Wu 、 Chia-Chang Wu 、 Chia-Hung Liu 、 Yi-Te Chiang 、 Kai-Yi Tzou 、 Wei-Tang Kao 、 Su-Wei Hu 、 Wen-Ling Wu 、 Mei-Yi Wu 、 Lie-Yee Hung 、 Cai-Mei Zheng 、 Yu-Wei Chen 、 Chia-Te Liao 、 Cheng-Hsien Chen 、 Hui-Wen Chiu 、 Po-Han Yu 、 Tze-Wah Kao 、 Kuan-Hung Lin


【SKMH】 Yuh-Mou Sue 、 Chu-Lin Chou

Chief : Mai-Szu Wu (President, TMU) 、 Chih-Cheng Hsu (Professor, NHRI) 、 Ke-Hung Tsui (Vice President, SHH) 、 Shing-Hwa Lu

Agenda :

1. Progress report on the renal and urinary precision health plan and biological sample database

2. School-level research center indicator tracking
3. Urinary and Kidney Cancer Team
4. Severe Kidney Disease Team



腎臟泌尿精準健康計畫及生物檢體資料庫進度報告

報告人：吳逸文 副教授

114年5月22日

腎病精準醫學計畫：改變疾病照護策略，實現數位精準管理



S1

建立精準照護流程

S2

培育基因專業人才

S3

驗證精準照護效益

【基因檢測】建立檢體及定序流程

【基因檢測】結果判讀及報告

【基因資料庫】建立世代研究族群

【公衛環境】建立公衛及環境測值

【基因體學】基因分析人員培育與訓練

【遺傳諮詢】建立諮詢內容及訓練

【精準治療】建立基因建議介入項目

【驗證療效】確認精準檢測與預後關係

【臨床應用】數位精準管理

2024
04

2024
06

2024
12

2025
03

2025
12

2

Action plans

Follow-up consultation



2024

04

05

06

08

12

2025
03

Cohort building

Panel construction
Scaled-up testing

Software application for history analysis

• Data interpretation
• Actionable items

Follow-up



Samples

- CKD=200
- ESKD=200
- Control=100

• WES
• Gene panel construction

EMR :
• SDOH
• Family aggregation

Actionable plan

• Genetic counseling
• Family consultation

數據處
OFFICE OF DATA SCIENCE

TMUCRD
Patient selection



Public health
Questionnaire

TMUCRD
EMR mining

Public health
On-site survey

3

Exploratory phase: samples from biobank




Parameters	Normal control, n = 100	CKD, n = 200	ESKD, n = 200	P-value
Age, years	62.45 (13.07)	61.87 (13.00)	61.74 (13.13)	0.902
Male, No. (%)	63 (63.00)	124 (62.00)	126 (63.00)	0.975
Hypertension, No. (%)	0 (0.00)	70 (35.00) ^c	186 (93.00) ^c	< 0.001*
Obesity, No. (%)	1 (1.89) ^b	15 (8.82)	28 (15.56) ^b	0.010*
Diabetes, No. (%)	0 (0.00)	47 (23.50) ^c	127 (63.50) ^c	< 0.001*
Laboratory data				
eGFR, mL/min per 1.73 m ²	90.74 [80.22, 106.19] ^{a, b}	60.00 [48.97, 75.19] ^{a, c}	8.22 [5.80, 15.83] ^{b, c}	< 0.001*
BUN, mg/dL	16.50 [13.00, 18.81] ^b	18.17 [14.50, 26.38] ^c	60.30 [49.30, 73.53] ^{b, c}	< 0.001*
Serum albumin, g/dL	4.38 (0.52) ^b	4.37 (0.41) ^c	3.71 (0.46) ^{b, c}	< 0.001*
Cholesterol, mg/dL	200.93 (31.42) ^{a, b}	180.58 (28.53) ^{a, c}	166.88 (33.89) ^{b, c}	< 0.001*
Glycohemoglobin (HbA1c), %	5.70 [5.44, 5.90] ^b	5.86 [5.52, 6.54]	6.07 [5.50, 7.16] ^b	0.015*
Glucose, mg/dL	101.08 [93.94, 109.00] ^b	102.20 [95.50, 115.39] ^{b, c}	117.47 [102.31, 155.87] ^c	< 0.001*

a The comparison between Normal group and CKD group is significant at the 0.05 level.

b The comparison between Normal group and ESRD group is significant at the 0.05 level.

c The comparison between CKD group and ESRD group is significant at the 0.05 level.

精準腎臟健康計畫進度及未來方向：



Journal Biomedical Science, under review

Current Polygenic Risk Score Testing

- Western population-predominant
- Array-based
- Partial transethnic transferability
- Lack gene-environmental interaction

PGS	Trait	Population	Discovery sample size	Discovery ancestry	Validation cohort
PGS000883 (PGS_GFR)	Incident CKD = eGFR of 60 ml/min per 1.73m ² plus ≥30% eGFR decline during a follow-up visit compared with baseline	UK Biobank + CKDGen	1,159,871	White = 82%; East Asian = 14.4%; South Asian = 1.8%; Black = 1.5%; Hispanic = 0.42%	ARIC
PGP000269 (PGS_CKD_53)	Case = eGFR <60 ml/min per 1.73 m ² Control = eGFR >90 ml/min per 1.73 m ²	70% of UKBB Europeans	177,208	European/White = 100%	CKDGen, UK Biobank, eMERGE-IL, BioMe, UAB
PGS000664 (PGS_decline_2021)	eGFRcrea decline: 3 ml/min per 1.73 m ² per year, eGFRcrea decline ≥25%, and eGFRcrea <60 ml/min per 1.73 m ² at follow-up among those with eGFRcrea 60 ml/min per 1.73 m ²	41 Studies from CKDGen and UK Biobank	>2,700,000	NA	Validated alternate kidney markers
Gorski 2022 ²⁷ (PGS_decline_2022)	Decline in eGFR ml/min per year (eGFR at follow-up - eGFR at baseline/number of follow-up years)	CKDGen, UK Biobank	343,339	White = 74%	The Trandeflag Health Study
PGS000822 (PGS_ACR)	Cases = urine ACR > 30 mg/g, Control = urine ACR < 10 mg/g	CKDGen, UK Biobank	564,257	White = 97%; East Asian = 1.1%; South Asian = 0.4%; Black = 1.2%; Latin = 0.3%	CKDGen Consortium


Bakshi A et al, Kidney Int, 2023

6


Prediction performance of PRS is under-represented in Asian population



a. CKD-PRS stratified by APOL1 risk gene




b. CKD-PRS stratified by ancestry




Khan A et al, Nat Med, 2022


7



Implication of ESKD polygenic scores according to comorbidities




Validation of the ESKD PGS in the Asian population from All of Us cohort.




Journal Biomedical Science, under review

10

Comparison of PRS across different CKD models and platforms



Prediction performance between array-based PRS and WGS-based PRS



* CKD cases (red), ESKD cases (gray), controls (green), and overlapping regions (brown)

建置暴露體數據平台：優化腎病健康及環境問卷



Gene-Environment interaction:

從代謝疾病及肺癌開始(有基因數據)
在HIS架構下建立個人的暴露體資料
在數據處建置暴露體數據資料庫
串聯外部資料庫




SurveyCake 問卷平台



<https://tmu.surveycake.biz/s/NwVWe>

精準腎臟健康計畫

Samples from TMU Biobank



Disease	No. case	進度
Normal control	100	8/30完成定序
CKM stage1 (Obesity)	200	未來可增加組別
CKM stage 2 (CKD)	200	8/16完成定序
CKM stage 4b (ESKD)	200	8/9 完成定序

目前進度：

- Library construction and WES reporting (9/19)
- TMU-TPMI data analysis: IRB revision (10/14 核准)
 - + Serum/Urine: Multi-omic analysis
 - + Exposome
 - + TMUCRD data mining
- TPMI array: 500 例-DNA完成出庫 (9/30)，結果 (10/16)

Pending:

- GWAS analysis and first draft (10/31)
- TMUCRD: 數據處理


原500例，送WGS (台基盟)：16,000 NT *500= 800萬

蔡世峰老師案



Large Scale WGS Cohort Targeting Four Linked Common Diseases in Taiwan (by 2025)

AGD Taiwan



One campus: 共同收案，共享資料，共同發表



Prospective Genomic Cohort Establishment:

Prospective cohort: 106



高治圻/吳逸文

IgA nephropathy



廖家德/林冠宏

Polycystic kidney disease



吳岳霖

Other kidney disease

年度	月份	腎臟科_雙和_血液	腎臟科_附屬_血液	腎臟科_萬芳_血液
2024	7	0	1	0
2024	8	0	2	0
2024	9	0	7	0
2024	10	0	13	0
2024	11	0	11	0
2024	12	0	18	0
2025	1	0	12	0
2025	2	0	10	1
2025	3	2	10	0
2025	4	1	17	1

目前成果

- 教育部高教深耕計畫：腎病精準醫學計畫（2024, 2025）
- 國際研討會：台灣腎臟醫學會：台馬泰國際研討會 (2024/12)
- 國內研討會：台基盟X國衛院：2025 精準論壇 (2025/04)
- 論文：Polygenic Score for Kidney Function and Clinical Management through Whole-Exome Sequencing in the Taiwanese Population (審查中)
- 計畫：
- 國科會：2 件（審查中）
- 國衛院計畫：2 件（審查中）



論文內容：



Parameters	Normal control, n = 100	CKD, n = 200	ESKD, n = 200	P-value
Age, years	62.45 (13.07)	61.87 (13.00)	61.74 (13.13)	0.902
Male, No. (%)	63 (63.00)	124 (62.00)	126 (63.00)	0.975
Hypertension, No. (%)	0 (0.00)	70 (35.00) ^c	186 (93.00) ^c	< 0.001*
Obesity, No. (%)	1 (1.89) ^b	15 (8.82)	28 (15.56) ^b	0.010*
Diabetes, No. (%)	0 (0.00)	47 (23.50) ^c	127 (63.50) ^c	< 0.001*
Laboratory data				
eGFR, mL/min per 1.73 m ²	90.74 [80.22, 106.19] ^{a, b}	60.00 [48.97, 75.19] ^{a, c}	8.22 [5.80, 15.83] ^{b, c}	< 0.001*
BUN, mg/dL	16.50 [13.00, 18.81] ^b	18.17 [14.50, 26.38] ^c	60.30 [49.30, 73.53] ^{b, c}	< 0.001*
Serum albumin, g/dL	4.38 (0.52) ^b	4.37 (0.41) ^c	3.71 (0.46) ^{b, c}	< 0.001*
Cholesterol, mg/dL	200.93 (31.42) ^{a, b}	180.58 (28.53) ^{a, c}	166.88 (33.89) ^{b, c}	< 0.001*
Glycohemoglobin (HbA1c), %	5.70 [5.44, 5.90] ^b	5.86 [5.52, 6.54]	6.07 [5.50, 7.16] ^b	0.015*
Glucose, mg/dL	101.08 [93.94, 109.00] ^b	102.20 [95.50, 115.39] ^{b, c}	117.47 [102.31, 155.87] ^c	< 0.001*

a The comparison between Normal group and CKD group is significant at the 0.05 level.

b The comparison between Normal group and ESKD group is significant at the 0.05 level.

c The comparison between CKD group and ESKD group is significant at the 0.05 level.

Methods

A well-defined hospital-based cohort with strict clinical diagnosis




Whole-exome sequencing of rare variants (MAF < 5%)

Missense Pathogenic

Polygenic score (PGS)


Validate in All of Us Asian cohort

Results




The study highlight the importance of preventive strategies and precision medicine in kidney disease management.

Polygenic scores predict renal function beyond comorbidities



20

Validation of Polygenic scores with All of US cohort



21



績效指標	目標值	Q1 (8-10)			Q2 (11-1)			Q3 (2-4)			Q4 (5-7)			當責者
		目標值	實際值	達成率	目標值	實際值	達成率	目標值	實際值	達成率	目標值	實際值	達成率	
三院AKD 收案量年 增率10% (現況累 計330例)	380	350	351 T:0 W:59 S:292	100.3%	360	374 T:0 W:66 S:308	103.9%	370	413 T:6 W:81 S:326	116.2%	380			(T)吳逸文 (W)鄭仲益 (S)廖家德
三院攝護 腺癌局部 精準治療 (海福刀)	60例	15	14 T:4 W:0 S:10	93.3%	15	12 T:2 W:0 S:10	80%	15	24 T:12 W:2 S:10	160%	15			(T)劉明哲 (W)林雍偉 (S)吳佳璋



Intergrated Chip Provide Rapid Identification of Uropathogen

Taipei Medical University – Department of Urology

Speaker : Associated Professor, Chia-Hung Liu , M.D..PhD.

Urinalysis



- Screening of urine samples is the third most frequently performed test in the clinical laboratories .[1]
- Urinalysis generally includes two kinds of methods: strip tests and microscopic examinations . [1]
- Urine microscopy, urine sediment analysis using microscope, has been used to detect various urologic diseases affecting from kidney to urinary tract. [1][2]
- **However, manual microscopic examination is time consuming and needs experts for interpretation .**

1. Zaman Z. Automated urine screening devices make urine sediment microscopy in diagnostic laboratories economically viable. Clin Chem Lab Med 2015;53:s1509-11.
2. Becker GJ, Garigalt G, Fogazzi GB. Advances in urine microscopy. Am J Kidney Dis 2016;67:954-64.

2

strip tests




manual method

Scan the Strip by Color CCD Sensor

US original color CCD sensor image analysis system enabling high-accuracy measurement.

Color CCD sensor image analysis system



automated method

Each person will vary in the operation of meter , the amount of urine , the light in environment used in the reading

3

strip tests-home test



Video clip adapted from Stanford News ,2016

Stanford University

This easy-to-assemble black box is part of an experimental urinalysis testing system designed by Stanford engineers. The black box is meant to enable a smartphone camera to capture video that accurately analyzes color changes in a standard paper dipstick in order to detect conditions of medical interest.

4

urine sediment analysis ?



1. Manual microscopic examination ?
2. Laser-based flow cytometry and digitized microscopy

ABC	WBC	WBC clumps
Squamous EC	Epithelial EC	Renal tubular EC
Hyaline cast	Cyst	Crystals
Trichocytes	Yeast	Sperm

■ Capturing by automatic focus

Capturing by NEIR high resolution digital camera. Output images with background like microscopy.

(Captured image)

■ Operation flow chart

```

graph TD
    USCANNER[USCANNER (promio)] --> Normal
    USCANNER --> Image_Review[Image Review]
    Image_Review --> Normal
    Image_Review --> Microscopy[Microscopy]
    Image_Review --> Result_Report[Result Report]
    Microscopy --> Result_Report
    
```

5

Goals




1. The present study proposes a unique approach for the quick and cost-effective ,
quantitative detection of Escherichia coli (E. coli) in urine samples using disposable
gold electrode sensing chips
2. Synthesized metal organic framework (MOF) Pd@VNU-1(Zr)-SH modified
Biosensor on a screen-printed electrode (SPE) displayed a very acceptable and
accurate results like sensitivity, limit of detection (LOD) and a very good selectivity.
3. Where all those obtained through the cyclic voltammogram (CV) and square wave
voltammograms (SWV)

6


Material and method



Cyclic Voltammetry and Square wave voltammetry




Cyclic Voltammetry



Square wave voltammetry

7


Material and method



Isopropyl β-D-1-thiogalactopyranoside (IPTG) is a molecular mimic of allolactose and not metabolized by *E. coli*, can induce β-gal expression in *E. coli*

8

Material and method




Concentration of *E. coli* ↑ + β-galactosidase ↑, hydrolysis of p-APG ↑
the oxidation current of p-APG ↓

p-aminophenyl-β-D-galactopyranoside (p-APG) is an isomer of galactose

9

Material and method




Cyclic Voltammetry

Square wave voltammetry

10


Materials and methods



1. Reference electrode (RE)
2. Counter electrode (CE)
3. Working electrode (WE)


11

Materials and methods- Pd@VNU-1(Zr)




12

Materials and methods- Pd@VNU-1(Zr)




13

Materials and methods- Pd@VNU-1(Zr)




14

Results Pd@VNU-1(Zr)




15

Results







16

Results



17



18

TMU-JIRB Form/No.2020017

Taipei Medical University Certificate of TMU-JIRB Approval

Issue Date: 2022/06/20

TMU-JIRB No.: N002200005

Protocol Title: Development of a high-sensitivity electrochemical sensor for rapid urine microbial detection

Principal Investigator: Chia-Hung - Lin

CO-Investigator: Fan Yu-fai

Study Member: Chia-Pin Hsu

Study Site: TMU-Shuang-Hsi Hospital

Protocol Version/Date: Version 2.0/2022.06.15

Informed Consent Form: Version6/2022/06/08

Case Report Form: Version1.0/11.03.02

The above study will be approved by expedited review process of the TMU-Joint Institutional Review Board in meeting #111-07-20date:2022/07/12, duration of validity is from 2022/06/21 to 2023/06/20, and must be monitored by TMU-JIRB.

According to Ministry of Health and Welfare and the relevant regulations, follow-up procedures and requirements are as below:

1. Continuing Report: Continuous report frequency is every 12 months. The report should be submitted in 2 months before the end of validity (2023-04-20). The trial/study cannot going if the continuous report not approve yet.
2. Final Report: The report should be submitted when the trial/study complete. TMU-JIRB will withdraw the approval of this trial/study if the report is not submitted final report within three months from the date of validity of this trial/study. Also, suspend principal investigator's right of new trial/study application in accordance with TMU-JIRB SOP for three months.
3. Serious Adverse Events(SAE) Report: The investigator is required to report in accordance with "Regulations for Good Clinical Practice" and "Procedures for Reporting Serious Adverse Drug Reaction".

Chairman:

Walter H. Shau, MD

臺北醫學大學附設醫院
聯合人體研究倫理委員會
Taipei Medical University
Joint Institutional Review Board

本中心核准執行之研究計畫
The TMU-Joint Institutional Review Board performs the functions according to written
operating procedures and complies with GCP and with the applicable regulatory requirements.
TMU-JIRB Form/No.2020017

Results



Follow-up bacterial culture quantification (μ l)	Urine Infection Judgment Result A	Electrodes Quantitative results	Reduction in oxidized area	Electrode fragment area determination result	Electrode Judgment Result B
8.6	negative	5.3	2700	0	negative
13.4	negative	5.3	2700	0	negative
15.8	negative	7.1	3900	0	negative
26.8	negative	11.2	6600	0	negative
43	negative	3.5	1500	0	negative
67.7	negative	22.6	8100	0	negative
188.3	positivity	24.4	3000	3000	positivity
890	positivity	13.4	12856	12856	positivity
1599	positivity	5.8	14279	14279	positivity
4372.3	positivity	20.6	21327	21327	positivity
66.4	negative	22.7	16508	0	negative

20

Conclusion



1.The proposed biosensor successfully detected urine bacterial counts with a sensitivity of about 75 colony-forming units per millilitre (cfu/ml), despite difficulties in detecting extremely low E. coli concentrations.

Both modified and unmodified gold electrodes showed an inversely proportional oxidation peak at 500 mV for p-PAG in E. Coli experiments employing SWV, with the modified electrodes showing greater sensitivity


2.The use of electrochemical techniques resulted in a significant decrease in experimental time, allowing real-time analysis for useful applications in the detection of bacteria in urine.

21

Acknowledgement



This work was supported by the National Science and Technology Council (NSTC) of Taiwan under grant numbers NSTC 112-2636-E-038 -003, and by jointed founding of Taipei Medical University and Shuang Ho Hospital under grant number 111TMU-SHH-. We would also like to thank the Semiconductor Fabrication Lab of the Consortia of Key Technologies, and the Nano-Electro-Mechanical-System Research Center, National Taiwan University for facility support.



重症腎病團隊

報告人：高治圻

114.5.22


組織架構



醫院	姓名	個人經歷	專長
北醫	高治圻	腎臟內科主治醫師 急重症透析	Clinical nephrology、Critical care
	陳靜怡	腎臟內科主治醫師 一般醫學、醫學教育	Clinical nephrology、Critical care、Medical education
	邵月珠	腎臟內科主治醫師 高齡醫學	Clinical nephrology、Geriatric medicine
萬芳	劉崇德	腎臟內科主治醫師	Clinical nephrology、Vascular access
	楊韻紅	腎臟內科主治醫師 急重症透析	Critical-care nephrology
雙和	洪麗玉	腎臟內科主治醫師 急重症透析	Clinical nephrology、Critical care
	林冠宏	腎臟內科主治醫師	Clinical nephrology、Critical-care dialysis

1

Critical-ill patients



2

Clinical samples collection



Project 1

Early AKI / AKD recognition biomarker

110/8/20~114/5/20, 收案96個病人, 含血液與尿液檢體

Project 2

Sarcopenia change in Critical-ill AKI patients

112/12/13~114/5/20, 收案63個病人, 含血液及尿液檢體

3

Early AKI / AKD biomarker



Characteristic	S-AKI	Sepsis-only	p value
N	29	23	
Male, n (%)	17 (58.6%)	11 (47.8%)	0.576
Age, years	74.0 (59-81)	69.0 (56-77)	0.524
Laboratory data			
Hb (g/dL)	10.0 (8.1-11.3)	10.1 (8.3-11.1)	0.808
WBC (n/ μ L)	11040 (7920-17480)	10820 (8670-15810)	0.912
Albumin (g/dL)	3.0 (2.5-3.4)	3.0 (2.5-3.2)	0.787
BUN (mg/dL)	60 (28-84)	17 (14-25)	<0.0001
Glucose (mg/dL)	121 (103.8-179.5)	178 (119-217)	0.199
CRP (mg/dL)	11.9 (6.3-24.2)	6.8 (3.6-17.4)	0.125
Cr (mg/dL)	2.1 (1.4-3.8)	0.6 (0.6-0.8)	<0.0001
eGFR (mL/min)	29 (15-45)	107 (97-133)	<0.0001
Infection ^a			
Gram-positive bacteria (%)	6 (21%)	6 (27%)	
Gram-negative bacteria (%)	21 (72%)	15 (68%)	0.827
Gram-positive+negative bacteria (%)	2 (7%)	1 (5%)	
Medical history, n (%) ^c			
Diabetes mellitus	9 (31%)	10 (43.5%)	0.396
Congestive heart failure	4 (13.8%)	2 (8.7%)	0.682
Coronary artery disease	4 (13.8%)	3 (13.0%)	>0.999
Hypertension	21 (72.4%)	14 (60.9%)	0.552
Chronic obstructive pulmonary disease	2 (6.9%)	2 (8.7%)	>0.999
Cancer	3 (10.4%)	2 (8.7%)	>0.999
Liver disease	0 (0%)	0 (0%)	>0.999
Chronic kidney disease (CKD)	13 (48.4%)	2 (8.7%)	0.005
Severity at the time of ICU ^b			
SOFA	5 (4-7)	3 (2-4.5)	0.009
APACHEII	16 (12-19)	13 (8.5-17)	0.099

Under review

4

Early AKI / AKD biomarker




Gene name	Fold change (S-AKI/ Sepsis-only) (D)	p value (D)	Fold change (S-AKI/ Sepsis-only) (F1)	p value (F1)	Fold change (S-AKI/ Sepsis-only) (F2)	p value (F2)
FABP4	2.52(↑)	0.0175	45.35(↑)	0.0067	8.88(↑)	0.0100
MYOC	3.03(↑)	0.0183	12.39(↑)	0.0382	10.54(↑)	0.0494
LYZ	9.65(↑)	0.0212	48.28(↑)	5.5125E-4	7.07(↑)	0.0038
PFN1	2.25(↑)	0.0420	4.27(↑)	1.0306E-4	3.80(↑)	0.0126
CFD	16.56(↑)	0.0468	69.76(↑)	0.0228	87.13(↑)	0.0021

Urine EV, proteomics analysis, DEP (differentially expressed proteins)

Under review

5

Early AKI / AKD biomarker




Under review

6

Sarcopenia change in Critical-ill AKI patients




IRB 112/12/13已通過，到114/5/20為止，已收案63個病人



* Gold standard for muscle mass: paraspinal muscle surface area at L4 (CTMSA)

Evaluate sarcopenia in critical-ill to predict outcomes

Sarcopenia change in Critical-ill AKI patients



-MAKE (major adverse kidney events)
 -QFMT (quadriceps femoris muscle thickness)
 -SI (sarcopenia index)
 -BCM (body composition monitor)

Sarcopenia change in Critical-ill AKI patients



- P: critical-ill AKI patients
- I: sarcopenia (+)
 - SARC-F量表(≥ 4 , <4)
 - Quadriceps femoris muscle thickness (QFMT) D1 D8; Change of QFMT
 - Sarcopenia index (serum Cr / cystatin C)
 - CT $\rightarrow$ lumbar skeletal muscle area
- C: sarcopenia (-)
- O: mortality, renal outcomes, CV outcomes

Demographics



	Total (N = 58)	Sarcopenia (N = 27)	Non-sarcopenia (N = 29)	P value
Age, years (mean $\pm$ SD)	75 $\pm$ 15	82 $\pm$ 15	69 $\pm$ 11	<0.01
Male (n, %)	36 (62%)	14 (52%)	20 (69%)	0.19
APACHE II score	26 $\pm$ 10	28 $\pm$ 9	22 $\pm$ 10	0.04
SOFA score	8 $\pm$ 5	9 $\pm$ 6	7 $\pm$ 4	0.14
CFS score	5 $\pm$ 3	7 $\pm$ 2	3 $\pm$ 2	<0.01
QFMT (mean $\pm$ SD)				
D1	2.6 $\pm$ 1.1	2.5 $\pm$ 1.0	2.6 $\pm$ 1.0	0.80
D8	2.6 $\pm$ 1.3	2.4 $\pm$ 1.0	2.5 $\pm$ 1.1	0.83
BMI	23.8 $\pm$ 5.0	22.3 $\pm$ 4.4	25.1 $\pm$ 5.3	0.03
Creatinine	1.9 (1.0-3.0)	2.2 (1.9-3.1)	3.0 (1.6-4.5)	0.44
eGFR	34 (20-66)	25 (16-33)	25 (14-41)	0.89
Albumin	3.1 $\pm$ 1.0	3.1 $\pm$ 0.5	3.1 $\pm$ 0.5	0.89
Lactate	16 (12-39)	17.6 (13.4-67.5)	13.4 (9.1-25.9)	0.02
Outcomes				
In-hospital mortality	17 (29%)	11 (41%)	6 (21%)	0.10



洗腎病人感染 COVID-19 後使用 Clexane 的安全性與療效分析

研究背景



- COVID-19 is associated with high risk of micro- and macrovascular thrombosis and raised incidence of anticoagulation failure
- Unlike conventional sepsis, anticoagulation plays a key role in management of COVID-19 with a positive impact on survival
- 洗腎病人感染 COVID-19 後有較高的血栓與死亡風險, 使用 Clexane 預防血管通路阻塞及可能增加出血風險

研究背景



Table 1. Difference in coagulation parameters between COVID-19 and conventional sepsis.

Variable	COVID-19 sepsis	Conventional sepsis
aPTT	N/↑	↑↑/↑↑↑
PT	N/↑	↑↑/↑↑↑
Fibrinogen	↑↑↑/↑↑/↓	↑↑↑/↑↑/↓
Thrombocytopenia	N/↓	↓↓/↓↓↓
FSP	↑/↑↑	↑↑/↑↑↑
D-Dimer	↑↑/↑↑↑	↑/↑↑
Schistocytes on peripheral blood smear	Not present	Frequent

Blood Rev. 2021; 47: 100761

13

研究目的



- 探討洗腎病人感染 COVID-19 使用 Clexane 對：
 - 血色素變化的影響
 - 血管通路阻塞風險
 - 出血事件風險
- 比較使用與未使用 Clexane 病人的臨床 outcome 差異

研究設計與方法



- 研究設計：retrospective study
- 研究期間：2020年05月～2024年12月
- 對象：確診COVID-19洗腎病人有/無使用 Clexane
- 資料來源：三院臨床資料庫/大同透析資料系統
- P: COVID19(+) hemodialysis patients
- I: IV Clexane
- C: Non-heparin or heparin (during dialysis)
- O: Hb, vascular access failure, bleeding risk

資料收集項目



基本資料	年齡、性別、共病、透析方式
COVID-19資料	住院天數、有無ICU、疾病嚴重程度 (SOFA score)
抗凝血藥物	Clexane使用劑量與天數
抽血數值	連續血色素、血小板、D-dimer、INR
Outcome	出血事件、通路阻塞、死亡率

預期貢獻



- 提供COVID-19疫情下，洗腎病人抗凝策略之安全性資料
 - 建立使用Clexane在洗腎病人的臨床參考依據
 - 有助於未來面臨高凝血疾病的延伸應用
-